UGT1A1 genotype does not affect tyrosine kinase inhibitors efficacy and safety in chronic myeloid leukemia

被引：5

作者：

Iurlo, Alessandra ^{[1
]}

Bucelli, Cristina ^{[1
]}

Cattaneo, Daniele ^{[1
]}

Levati, Giorgia Virginia ^{[1
]}

Viani, Benedetta ^{[1
]}

Tavazzi, Dario ^{[2
,3
]}

Consonni, Dario ^{[4
]}

Baldini, Luca ^{[1
]}

Cappellini, Maria Domenica ^{[2
,3
]}

机构：

[1] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Hematol Div, Milan, Italy

[2] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy

[3] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy

[4] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Epidemiol Unit, Milan, Italy

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2019年 / 94卷 / 11期

关键词：

RECOMMENDATIONS; CHEMOTHERAPY; MANAGEMENT; NILOTINIB;

D O I：

10.1002/ajh.25596

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E283 / E285

页数：3

共 50 条

[21] Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia [J].

Giles, F. J. ;

O'Dwyer, M. ;

Swords, R. .

LEUKEMIA, 2009, 23 (10) :1698-1707

[22] Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia [J].

F J Giles ;

M O'Dwyer ;

R Swords .

Leukemia, 2009, 23 :1698-1707

[23] A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia [J].

Kaddoura, Rasha ;

Dabdoob, Wafer A. A. ;

Ahmed, Khalid ;

Yassin, Mohamed A. A. .

FRONTIERS IN MEDICINE, 2023, 10

[24] Assessment of molecular response to tyrosine kinase inhibitors in Tunisian Patients with Chronic Myeloid Leukemia [J].

Frikha, Rim ;

Kassar, Olfa ;

Elloumi, Moez ;

Kamoun, Hassen .

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (08) :1826-1831

[25] When Can Tyrosine Kinase Inhibitors Be Discontinued in Patients With Chronic Myeloid Leukemia? [J].

Mahon, Francois-Xavier .

CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (02) :101-103

[26] Collaborative cardiovascular management of patients with chronic myeloid leukemia on tyrosine kinase inhibitors [J].

Kondapalli, Lavanya ;

Worth, Sarah ;

Hawi, Riem ;

Vachhani, Pankit ;

Arora, Garima ;

Bhatia, Ravi ;

Lenneman, Carrie G. .

VASCULAR MEDICINE, 2020, 25 (03) :246-254

[27] Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors [J].

Gugliotta, Gabriele ;

Castagnetti, Fausto ;

Fogli, Miriam ;

Cavo, Michele ;

Baccarani, Michele ;

Rosti, Gianantonio .

EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (05) :563-574

[28] Vascular complications in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors [J].

Cho, Hee Jeong ;

Sohn, Sang-Kyun .

JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2023, 66 (04) :224-233

[29] Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia [J].

Quintas-Cardama, Alfonso ;

Cortes, Jorge E. ;

Kantarjian, Hagop .

CLINICAL LYMPHOMA & MYELOMA, 2008, 8 :S82-S88

[30] Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review [J].

Santoro, Marco ;

Mancuso, Salvatrice ;

Accurso, Vincenzo ;

Di Lisi, Daniela ;

Novo, Giuseppina ;

Siragusa, Sergio .

FRONTIERS IN PHYSIOLOGY, 2021, 12

← 1 2 3 4 5 →